+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm



Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm



JAMA Dermatology 150(12): 1315-1321



IMPORTANCE Sebaceous neoplasms (SNs) define the Muir-Torre syndrome variant of Lynch syndrome (LS), which is associated with increased risk for colon and other cancers necessitating earlier and more frequent screening to reduce morbidity and mortality.Immunohistochemical (IHC) staining for mismatch repair (MMR) proteins in SNs can be used to screen for LS, but data on subsequent germline genetic testing to confirm LS diagnosis are limited.OBJECTIVE To characterize the utility of IHC screening of SNs in identification of germline MMR mutations confirming LS.DESIGN, SETTING, AND PARTICIPANTS Retrospective study at 2 academic cancer centers of 86 adult patients referred for clinical genetics evaluation after diagnosis of SN.MAIN OUTCOMES AND MEASURES Results of tumor IHC testing and germline genetic testing were reviewed to determine positive predictive value and sensitivity of IHC testing in diagnosis of LS. Clinical variables, including age at diagnosis of SN, clinical diagnostic criteria for LS and Muir-Torre syndrome, and family history characteristics were compared between mutation carriers and noncarriers.RESULTS Of 86 patients with SNs, 25 (29%) had germline MMR mutations confirming LS.Among 77 patients with IHC testing on SNs, 38 (49%) had loss of staining of 1 or more MMR proteins and 14 had germline MMR mutations. Immunohistochemical analysis correctly identified 13 of 16 MMR mutation carriers, corresponding to 81% sensitivity. Ten of 12 patients(83%) with more than 1 SN had MMR mutations. Fifty-two percent of MMR mutation carriers did not meet clinical diagnostic criteria for LS, and 11 of 25 (44%) did not meet the clinical definition of Muir-Torre syndrome. CONCLUSIONS AND RELEVANCE Immunohistochemical screening of SNs is effective in identifying patients with germline MMR mutations and can be used as a first-line test when LSis suspected. Abnormal IHC results, including absence of MSH2, are not diagnostic of LS and should be interpreted cautiously in conjunction with family history and germline genetic testing. Use of family history to select patients for IHC screening has substantial limitations,suggesting that universal IHC screening of SNs merits further study. Clinical genetics evaluation is warranted for patients with abnormal IHC test results, normal IHC test results with personal or family history of other LS-associated neoplasms, and/or multiple SNs.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055671751

Download citation: RISBibTeXText

PMID: 25006859

DOI: 10.1001/jamadermatol.2014.1217


Related references

Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient's age or other clinical characteristics. American Journal of Surgical Pathology 33(6): 934-944, 2009

Screening for germline mutations in mismatch repair genes in patients with Lynch syndrome by next generation sequencing. Familial Cancer 17(3): 387-394, 2017

Clinical consequences of molecular diagnosis in families with mismatch repair gene germline mutations. International Journal of Colorectal Disease 15(5-6): 255-263, 2000

A novel germline mutation in the hMLH1 DNA mismatch repair gene in a patient with an isolated cystic sebaceous tumor. Journal of Investigative Dermatology 112(1): 117-118, 1999

Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test. American Journal of Surgical Pathology 26(3): 338-343, 2002

Cancer risk associated with germline DNA mismatch repair gene mutations. Human Molecular Genetics 6(1): 105-110, 1997

Determining the frequency of de novo germline mutations in DNA mismatch repair genes. Journal of Medical Genetics 48(8): 530-534, 2011

Streamlining the use of IHC in identifying germline mismatch repair mutations in Lynch syndrome. Ulster Medical Journal 81(2): 98-99, 2014

Childhood brain tumours due to germline bi-allelic mismatch repair gene mutations. Clinical Genetics 80(3): 243-255, 2011

Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies. Cancer 109(11): 2349-2356, 2007

Sebaceous neoplasms and the immunoprofile of mismatch-repair proteins as a screening target for syndromic cases. Pathology, Research and Practice 211(1): 78-82, 2015

Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms. Journal of Genetic Counseling 22(3): 393-405, 2013

Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology 147(6): 1308-1316.E1, 2015

Germline mutations of mismatch repair genes in patients with HNPCC-like syndrome Preliminary results. Gastroenterology 112(4 SUPPL ): A549, 1997

Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer. International Journal of Cancer 126(4): 930-939, 2010